Cabela's stock surges after feds appove buyout. Johnny Morris is a business genius.

With 94 Bass Pro Shops and 82 Cabela's plus a massive online catalog department the future will be huge for Emesyl.

Maybe that's what has happened or maybe one of his managers from one of his stores in Florida that deep sea fishes a lot uses Emesyl and told Mr Morris about it.

You will see in the months to come.

People all over the world know who Johnny Morris is. He knows how to Market a product. His net worth is 6 billion dollars. He owns Bass Pro Shops, Cabela's and many other stores.

Johnny Morris to buy Itonis Inc and sell Emesyl in everyone of his stores????

Maybe the owner of Bass Pro Shops and Cabela's will buy the Company and sell Emesyl in all his stores.

Load up everyone 2017 will be the year

$$itns .17 coming soon

While you are lyao buy some more shares

The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues. The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. $$$.17 Eminent.

Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.
Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20 staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.
Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law. $$ITNS$$.17

Dr. Donald L. Jolly, Ph.D. has more than 20 years experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a California bank provided him valuable experience in managing the early developments of a business.
Dr. Jolly also serves as the Chairman and CEO of the Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in Hyperbarics. He has studied in London, Aberdeen, Scotland and California with internationally renowned doctors, developed research facilities in California, worked in Africa and Romania, and made great strides in research as well as the application of Hyperbaric Oxygen Therapy (HBOT). This pursuit has supplemented his banking career with additional operational and business growth experience.$$ITNS$$.17

Dr Hensley took Zicam as a publicly traded company to multiple dollars on the Nazdaq before selling the company. $$ITNS will do the same with Emesyl $$ITNS$$ .17 Get in now.

Dr Hensley took Zicam as a publicly traded company to multiple dollars on the Nazdaq before selling the company. $$ITNS will do the same with Emesyl

Dr. Donald L. Jolly, Ph.D. has more than 20 years experience in the Finance Industry. He has served at both the board and executive levels within the banking community, holding numerous executive positions ranging from the Vice President of Marketing to the President/CEO of several California banks. His wide array of corporate and retail experience include all aspects of banking operations, loans, marketing, personnel, and customer relations. His founding of a California bank provided him valuable experience in managing the early developments of a business.
Dr. Jolly also serves as the Chairman and CEO of the Richard A. Neubauer Research Institute, a 501(c)(3) non-profit organization established to further research, medical improvements, and education in Hyperbarics. He has studied in London, Aberdeen, Scotland and California with internationally renowned doctors, developed research facilities in California, worked in Africa and Romania, and made great strides in research as well as the application of Hyperbaric Oxygen Therapy (HBOT). This pursuit has supplemented his banking career with additional operational and business growth experience.

Mr. Pidliskey serves as Vice President and Secretary for Itonis, Inc. He is responsible for the management of all company operations and is a visionary leader with a proven track record in motivating, managing and growing large multi-level teams in support of new products and services.
Prior to joining Itonis, Inc. in 2011, Mr. Pidliskey was a Project Executive for IBM Corporation, retiring after a 32 year career. During his tenure with IBM, he was responsible for worldwide sales and services support with contract revenues exceeding $1B annually. He has extensive experience in leading large complex teams responsible for business operations, strategic planning, change management, business process reengineering, and technical sales support. As an Innovative leader, Mr. Pidliskey is known for building strong teams, integrating strategic business partnerships, and delivering high levels of client satisfaction to customer sets ranging from small and medium size businesses to Fortune 500 companies.
Within his community, Mr. Pidliskey has served as a county board member for more than 20 years to a local county government Citizens Advisory Council. He has held several executive positions on the council, and meets monthly with government and community leaders to assist in the development and perpetuation of crime prevention programs in support of law enforcement services. In addition, Mr. Pidliskey has served for over 10 years as a committee member to a local Boy Scout troop and remains active in leading fund raising activities in support of the Boy Scouts of America.

Mr. Cheung has more than 20 years of business law and entrepreneurial experience in the legal fields of business litigation and appeals. He has been a name partner at his Irvine, California law firm that has handled numerous business litigation and intellectual property matters, including a trademark case that ended favorably in the U.S. Supreme Court. Through years of litigation matters, Mr. Cheung has confronted unprecedented business operational disputes and relationship issues, providing industry opportunities to enhance and apply problem-solving skills at all levels.
Since 2001, Mr. Cheung has served on and chaired various not-for-profit boards for several organizations in Orange County, California. He chaired a consumer financial non-profit organization that included 20 staff, over $2 million in assets and $1.7 million in annual revenues. He has chaired at a community college foundation with over $1.5 million in assets and endowments. Mr. Cheung has also served as a board member to several attorney bar associations, including the chair position for one such association.
Mr. Cheung received his Bachelor of Arts degree in Economics from Brandeis University, and his law degree from Boston College Law School. He has also published scholarly articles in the law.

The Company will market Emesyl® to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch. Plans are in place to aggressively market Emesyl® for a significant share of the worldwide over-the-counter pharmaceutical market revenues. The more than 700 of over-the-counter (OTC) drugs on the market today required a prescription 30 years ago, and the shift to non-prescription OTC medicines has allowed consumers to reduce the number of doctor visits for minor ailments. The worldwide market for OTC drugs could exceed $70 billion by 2015, according to a report by Visiongain, a British research company. $$$.17 Eminent.

Itonis pleased to announce it received word from its Media Agency that the planned Ten Thousand (10,000) thirty (30) second commercial spots for its Emesyl® Nausea Relief product has begun. The ad is being run in about 240 small cable television systems in over 40 states, and cumulatively makes up a network of approximately 1.0M homes. These runs are at various times day and night, and across all the networks on the platform. $$$.17 Eminent.

Itonis, Inc. is pleased to announce that National Homeopathic Labs will be the new manufacturer for its anti-nausea product, Emesyl. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements for over 25 years.
Itonis has placed its first purchase order with National Homeopathic Labs and is expecting delivery of its first batch of product within the next 2 months.
We are very pleased to be working with National Homeopathic Labs and look forward to a long standing relationship with them said Steve Pidliskey, Itonis Vice President. Once they delivered the first batch of samples to us and we had time to test them, we immediately knew we had a sure winner.

$$ITNS 2017 will be the year. Emesyl will be in stores across the nation. $$.17 eminent. Time to load. Don't sit on the sidelines and miss out.

$$ITNS Strong buy. Myec & Webimax. $$.17 "SOON"

$$ITNS accumulating. Adding$.17 immenent

There is as huge difference between .0017 and $$.17 ITNS$$ will be huge. Emesyl will be huge. $$.17 will happen soon. Im loading the boat.

ITNS $$.17 will be here soon. Buy more. Load up.

I'm loading up itns buy more. ITNS & MYEC & WEBIMAX $$$.17

Hold on to your shares and buy more. $$ITNS .17

$$ ITNS & Emesyl in Walgreens/ CVS/ Wal-Mart & every cruise ship line in the near future. $$.17

$$ITNS .17 I will be loading all week.

$MYEC & $ITNS & Webimax= $$$$ .17 in 2017

$ITNS under tight watch $.15 golden cross coming.

$$ITNS$$ Myec and ITNS. $$.15

ITNS$$$ buy them cheap while you can. I'm loading in the morning. $$$.15

ITNS$$ Mark and Webimax working hard to make Emesyl a house hold name. $$$.15

ITNS$$ low float, few shares trading $$.15

ITNS$ shares recovered and cancelled in the near future ???

ITNS$ will be in every store by the end of 2017???

ITNS $.15

Lift off is never going to happen. This has already crashed and is burning.